View Future GrowthNational Peroxide 過去の業績過去 基準チェック /26National Peroxideの過去数年間の業績に関するデータが不十分です。主要情報n/a収益成長率n/aEPS成長率Chemicals 業界の成長17.68%収益成長率14.20%株主資本利益率4.63%ネット・マージン5.25%前回の決算情報30 Jun 2026最近の業績更新お知らせ • Jul 30National Peroxide Limited to Report Q1, 2027 Results on Aug 03, 2026National Peroxide Limited announced that they will report Q1, 2027 results on Aug 03, 2026Reported Earnings • May 05Full year 2026 earnings released: EPS: ₹19.20 (vs ₹3.91 loss in FY 2025)Full year 2026 results: EPS: ₹19.20 (up from ₹3.91 loss in FY 2025). Revenue: ₹2.96b (up 3.1% from FY 2025). Net income: ₹110.4m (up ₹132.8m from FY 2025). Profit margin: 3.7% (up from net loss in FY 2025). The move to profitability was primarily driven by higher revenue.お知らせ • Apr 29National Peroxide Limited to Report Q4, 2026 Results on Apr 30, 2026National Peroxide Limited announced that they will report Q4, 2026 results on Apr 30, 2026Reported Earnings • Feb 06Third quarter 2026 earnings released: EPS: ₹3.19 (vs ₹2.64 loss in 3Q 2025)Third quarter 2026 results: EPS: ₹3.19 (up from ₹2.64 loss in 3Q 2025). Revenue: ₹699.9m (up 13% from 3Q 2025). Net income: ₹18.3m (up ₹33.5m from 3Q 2025). Profit margin: 2.6% (up from net loss in 3Q 2025).お知らせ • Jan 22National Peroxide Limited to Report Q3, 2026 Results on Jan 28, 2026National Peroxide Limited announced that they will report Q3, 2026 results on Jan 28, 2026Reported Earnings • Nov 05Second quarter 2026 earnings released: EPS: ₹0.67 (vs ₹2.64 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹0.67 (up from ₹2.64 loss in 2Q 2025). Revenue: ₹699.5m (up 13% from 2Q 2025). Net income: ₹3.86m (up ₹19.0m from 2Q 2025). Profit margin: 0.6% (up from net loss in 2Q 2025).すべての更新を表示Recent updatesお知らせ • 17hNational Peroxide Limited, Annual General Meeting, Sep 29, 2026National Peroxide Limited, Annual General Meeting, Sep 29, 2026.お知らせ • Jul 30National Peroxide Limited to Report Q1, 2027 Results on Aug 03, 2026National Peroxide Limited announced that they will report Q1, 2027 results on Aug 03, 2026Buy Or Sell Opportunity • Jul 30Now 20% undervaluedOver the last 90 days, the stock has risen 25% to ₹569. The fair value is estimated to be ₹711, however this is not to be taken as a buy recommendation but rather should be used as a guide only.Buy Or Sell Opportunity • Jul 15Now 20% undervaluedOver the last 90 days, the stock has risen 40% to ₹564. The fair value is estimated to be ₹708, however this is not to be taken as a buy recommendation but rather should be used as a guide only.Buy Or Sell Opportunity • Jun 05Now 20% undervaluedOver the last 90 days, the stock has risen 35% to ₹560. The fair value is estimated to be ₹704, however this is not to be taken as a buy recommendation but rather should be used as a guide only.New Risk • May 27New minor risk - Dividend sustainabilityThe company has a short dividend paying track record. Less than a year of continuous dividend payments. Dividend yield: 1.2% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Short dividend paying track record (less than a year of continuous dividend payments). Market cap is less than US$100m (₹3.38b market cap, or US$35.3m).Valuation Update With 7 Day Price Move • May 08Investor sentiment improves as stock rises 43%After last week's 43% share price gain to ₹652, the stock trades at a trailing P/E ratio of 34x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 15% over the past year.Reported Earnings • May 05Full year 2026 earnings released: EPS: ₹19.20 (vs ₹3.91 loss in FY 2025)Full year 2026 results: EPS: ₹19.20 (up from ₹3.91 loss in FY 2025). Revenue: ₹2.96b (up 3.1% from FY 2025). Net income: ₹110.4m (up ₹132.8m from FY 2025). Profit margin: 3.7% (up from net loss in FY 2025). The move to profitability was primarily driven by higher revenue.New Risk • May 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 7.8% over the past year. Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₹3.15b market cap, or US$33.1m).お知らせ • Apr 29National Peroxide Limited to Report Q4, 2026 Results on Apr 30, 2026National Peroxide Limited announced that they will report Q4, 2026 results on Apr 30, 2026Board Change • Mar 31High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. CEO & Director Rajiv Arora is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Buy Or Sell Opportunity • Feb 24Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 27% to ₹402. The fair value is estimated to be ₹506, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 7.8% over the last year. Meanwhile, the company became loss making.Reported Earnings • Feb 06Third quarter 2026 earnings released: EPS: ₹3.19 (vs ₹2.64 loss in 3Q 2025)Third quarter 2026 results: EPS: ₹3.19 (up from ₹2.64 loss in 3Q 2025). Revenue: ₹699.9m (up 13% from 3Q 2025). Net income: ₹18.3m (up ₹33.5m from 3Q 2025). Profit margin: 2.6% (up from net loss in 3Q 2025).お知らせ • Jan 22National Peroxide Limited to Report Q3, 2026 Results on Jan 28, 2026National Peroxide Limited announced that they will report Q3, 2026 results on Jan 28, 2026Reported Earnings • Nov 05Second quarter 2026 earnings released: EPS: ₹0.67 (vs ₹2.64 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹0.67 (up from ₹2.64 loss in 2Q 2025). Revenue: ₹699.5m (up 13% from 2Q 2025). Net income: ₹3.86m (up ₹19.0m from 2Q 2025). Profit margin: 0.6% (up from net loss in 2Q 2025).お知らせ • Oct 29National Peroxide Limited to Report Q3, 2026 Results on Nov 03, 2025National Peroxide Limited announced that they will report Q3, 2026 results on Nov 03, 2025お知らせ • Jul 30National Peroxide Limited, Annual General Meeting, Sep 04, 2025National Peroxide Limited, Annual General Meeting, Sep 04, 2025, at 15:30 Indian Standard Time.Reported Earnings • Jul 30First quarter 2026 earnings released: EPS: ₹1.55 (vs ₹5.35 in 1Q 2025)First quarter 2026 results: EPS: ₹1.55 (down from ₹5.35 in 1Q 2025). Revenue: ₹686.8m (down 22% from 1Q 2025). Net income: ₹8.90m (down 71% from 1Q 2025). Profit margin: 1.3% (down from 3.5% in 1Q 2025). The decrease in margin was driven by lower revenue.お知らせ • Jul 24National Peroxide Limited to Report Q1, 2026 Results on Jul 29, 2025National Peroxide Limited announced that they will report Q1, 2026 results on Jul 29, 2025New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 14% over the past year. Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (₹4.22b market cap, or US$48.8m).お知らせ • May 01National Peroxide Limited to Report Q4, 2025 Results on May 06, 2025National Peroxide Limited announced that they will report Q4, 2025 results on May 06, 2025お知らせ • Mar 19National Peroxide Limited Announces Resignation of Munish Bakshi as Vice President - Marketing & Sales, with Effect from April 11, 2025National Peroxide Limited informed that Mr. Munish Bakshi, Vice President - Marketing & Sales of the Company, has given a notice of resignation from the post of Vice President - Marketing & Sales to pursue another opportunity. Resignation: To pursue other career opportunity. Cessation is with effect from 11th April, 2025.お知らせ • Jan 17National Peroxide Limited to Report Q3, 2025 Results on Jan 23, 2025National Peroxide Limited announced that they will report Q3, 2025 results on Jan 23, 2025お知らせ • Oct 24National Peroxide Limited to Report Q2, 2025 Results on Oct 29, 2024National Peroxide Limited announced that they will report Q2, 2025 results on Oct 29, 2024お知らせ • Aug 02National Peroxide Limited Recommends Dividend for the Year Ended March 31, 2024National Peroxide Limited at its board meeting held on May 09, 2024 had recommended payment of dividend at 125%, that is INR 12.50 per Equity Share of INR 10 each for the year ended March 31, 2024 subject To Approve the Members in the upcoming Annual General Meeting of the Members to be held on August 27, 2024. Final Dividend if declared, will be paid within the timelines prescribed under the law. The Board of Directors at its meeting held on July 31, 2024, approved closure of Register of Members and Share Transfer Books of the Company from August 21, 2024 to August 27, 2024 (both days inclusive) for the purpose of AGM and determining names of members entitled to receive Dividend to be declared at the AGM. Hence, the record date for the AGM and final dividend is August 20, 2024.お知らせ • Aug 01National Peroxide Limited, Annual General Meeting, Aug 27, 2024National Peroxide Limited, Annual General Meeting, Aug 27, 2024.お知らせ • Jul 25National Peroxide Limited to Report Q1, 2025 Results on Jul 31, 2024National Peroxide Limited announced that they will report Q1, 2025 results on Jul 31, 2024収支内訳National Peroxide の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史BSE:544205 収益、費用、利益 ( )INR Millions日付収益収益G+A経費研究開発費30 Jun 263,192168270031 Mar 262,897110265031 Dec 252,777-34258030 Sep 252,708-67276030 Jun 252,795-64296031 Mar 252,869-22304031 Dec 243,01273313031 Mar 243,3301682930質の高い収益: 544205は 高品質の収益 を持っています。利益率の向上: 544205過去に利益を上げました。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 544205の過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: 544205は昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。収益対業界: 544205昨年収益を上げたため、昨年の収益成長をChemicals業界 ( 19% ) と比較することは困難です。株主資本利益率高いROE: 544205の 自己資本利益率 ( 4.6% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/13 12:01終値2026/08/13 00:00収益2026/06/30年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋National Peroxide Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jul 30National Peroxide Limited to Report Q1, 2027 Results on Aug 03, 2026National Peroxide Limited announced that they will report Q1, 2027 results on Aug 03, 2026
Reported Earnings • May 05Full year 2026 earnings released: EPS: ₹19.20 (vs ₹3.91 loss in FY 2025)Full year 2026 results: EPS: ₹19.20 (up from ₹3.91 loss in FY 2025). Revenue: ₹2.96b (up 3.1% from FY 2025). Net income: ₹110.4m (up ₹132.8m from FY 2025). Profit margin: 3.7% (up from net loss in FY 2025). The move to profitability was primarily driven by higher revenue.
お知らせ • Apr 29National Peroxide Limited to Report Q4, 2026 Results on Apr 30, 2026National Peroxide Limited announced that they will report Q4, 2026 results on Apr 30, 2026
Reported Earnings • Feb 06Third quarter 2026 earnings released: EPS: ₹3.19 (vs ₹2.64 loss in 3Q 2025)Third quarter 2026 results: EPS: ₹3.19 (up from ₹2.64 loss in 3Q 2025). Revenue: ₹699.9m (up 13% from 3Q 2025). Net income: ₹18.3m (up ₹33.5m from 3Q 2025). Profit margin: 2.6% (up from net loss in 3Q 2025).
お知らせ • Jan 22National Peroxide Limited to Report Q3, 2026 Results on Jan 28, 2026National Peroxide Limited announced that they will report Q3, 2026 results on Jan 28, 2026
Reported Earnings • Nov 05Second quarter 2026 earnings released: EPS: ₹0.67 (vs ₹2.64 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹0.67 (up from ₹2.64 loss in 2Q 2025). Revenue: ₹699.5m (up 13% from 2Q 2025). Net income: ₹3.86m (up ₹19.0m from 2Q 2025). Profit margin: 0.6% (up from net loss in 2Q 2025).
お知らせ • 17hNational Peroxide Limited, Annual General Meeting, Sep 29, 2026National Peroxide Limited, Annual General Meeting, Sep 29, 2026.
お知らせ • Jul 30National Peroxide Limited to Report Q1, 2027 Results on Aug 03, 2026National Peroxide Limited announced that they will report Q1, 2027 results on Aug 03, 2026
Buy Or Sell Opportunity • Jul 30Now 20% undervaluedOver the last 90 days, the stock has risen 25% to ₹569. The fair value is estimated to be ₹711, however this is not to be taken as a buy recommendation but rather should be used as a guide only.
Buy Or Sell Opportunity • Jul 15Now 20% undervaluedOver the last 90 days, the stock has risen 40% to ₹564. The fair value is estimated to be ₹708, however this is not to be taken as a buy recommendation but rather should be used as a guide only.
Buy Or Sell Opportunity • Jun 05Now 20% undervaluedOver the last 90 days, the stock has risen 35% to ₹560. The fair value is estimated to be ₹704, however this is not to be taken as a buy recommendation but rather should be used as a guide only.
New Risk • May 27New minor risk - Dividend sustainabilityThe company has a short dividend paying track record. Less than a year of continuous dividend payments. Dividend yield: 1.2% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Short dividend paying track record (less than a year of continuous dividend payments). Market cap is less than US$100m (₹3.38b market cap, or US$35.3m).
Valuation Update With 7 Day Price Move • May 08Investor sentiment improves as stock rises 43%After last week's 43% share price gain to ₹652, the stock trades at a trailing P/E ratio of 34x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 15% over the past year.
Reported Earnings • May 05Full year 2026 earnings released: EPS: ₹19.20 (vs ₹3.91 loss in FY 2025)Full year 2026 results: EPS: ₹19.20 (up from ₹3.91 loss in FY 2025). Revenue: ₹2.96b (up 3.1% from FY 2025). Net income: ₹110.4m (up ₹132.8m from FY 2025). Profit margin: 3.7% (up from net loss in FY 2025). The move to profitability was primarily driven by higher revenue.
New Risk • May 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 7.8% over the past year. Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₹3.15b market cap, or US$33.1m).
お知らせ • Apr 29National Peroxide Limited to Report Q4, 2026 Results on Apr 30, 2026National Peroxide Limited announced that they will report Q4, 2026 results on Apr 30, 2026
Board Change • Mar 31High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. CEO & Director Rajiv Arora is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Buy Or Sell Opportunity • Feb 24Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 27% to ₹402. The fair value is estimated to be ₹506, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 7.8% over the last year. Meanwhile, the company became loss making.
Reported Earnings • Feb 06Third quarter 2026 earnings released: EPS: ₹3.19 (vs ₹2.64 loss in 3Q 2025)Third quarter 2026 results: EPS: ₹3.19 (up from ₹2.64 loss in 3Q 2025). Revenue: ₹699.9m (up 13% from 3Q 2025). Net income: ₹18.3m (up ₹33.5m from 3Q 2025). Profit margin: 2.6% (up from net loss in 3Q 2025).
お知らせ • Jan 22National Peroxide Limited to Report Q3, 2026 Results on Jan 28, 2026National Peroxide Limited announced that they will report Q3, 2026 results on Jan 28, 2026
Reported Earnings • Nov 05Second quarter 2026 earnings released: EPS: ₹0.67 (vs ₹2.64 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹0.67 (up from ₹2.64 loss in 2Q 2025). Revenue: ₹699.5m (up 13% from 2Q 2025). Net income: ₹3.86m (up ₹19.0m from 2Q 2025). Profit margin: 0.6% (up from net loss in 2Q 2025).
お知らせ • Oct 29National Peroxide Limited to Report Q3, 2026 Results on Nov 03, 2025National Peroxide Limited announced that they will report Q3, 2026 results on Nov 03, 2025
お知らせ • Jul 30National Peroxide Limited, Annual General Meeting, Sep 04, 2025National Peroxide Limited, Annual General Meeting, Sep 04, 2025, at 15:30 Indian Standard Time.
Reported Earnings • Jul 30First quarter 2026 earnings released: EPS: ₹1.55 (vs ₹5.35 in 1Q 2025)First quarter 2026 results: EPS: ₹1.55 (down from ₹5.35 in 1Q 2025). Revenue: ₹686.8m (down 22% from 1Q 2025). Net income: ₹8.90m (down 71% from 1Q 2025). Profit margin: 1.3% (down from 3.5% in 1Q 2025). The decrease in margin was driven by lower revenue.
お知らせ • Jul 24National Peroxide Limited to Report Q1, 2026 Results on Jul 29, 2025National Peroxide Limited announced that they will report Q1, 2026 results on Jul 29, 2025
New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 14% over the past year. Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (₹4.22b market cap, or US$48.8m).
お知らせ • May 01National Peroxide Limited to Report Q4, 2025 Results on May 06, 2025National Peroxide Limited announced that they will report Q4, 2025 results on May 06, 2025
お知らせ • Mar 19National Peroxide Limited Announces Resignation of Munish Bakshi as Vice President - Marketing & Sales, with Effect from April 11, 2025National Peroxide Limited informed that Mr. Munish Bakshi, Vice President - Marketing & Sales of the Company, has given a notice of resignation from the post of Vice President - Marketing & Sales to pursue another opportunity. Resignation: To pursue other career opportunity. Cessation is with effect from 11th April, 2025.
お知らせ • Jan 17National Peroxide Limited to Report Q3, 2025 Results on Jan 23, 2025National Peroxide Limited announced that they will report Q3, 2025 results on Jan 23, 2025
お知らせ • Oct 24National Peroxide Limited to Report Q2, 2025 Results on Oct 29, 2024National Peroxide Limited announced that they will report Q2, 2025 results on Oct 29, 2024
お知らせ • Aug 02National Peroxide Limited Recommends Dividend for the Year Ended March 31, 2024National Peroxide Limited at its board meeting held on May 09, 2024 had recommended payment of dividend at 125%, that is INR 12.50 per Equity Share of INR 10 each for the year ended March 31, 2024 subject To Approve the Members in the upcoming Annual General Meeting of the Members to be held on August 27, 2024. Final Dividend if declared, will be paid within the timelines prescribed under the law. The Board of Directors at its meeting held on July 31, 2024, approved closure of Register of Members and Share Transfer Books of the Company from August 21, 2024 to August 27, 2024 (both days inclusive) for the purpose of AGM and determining names of members entitled to receive Dividend to be declared at the AGM. Hence, the record date for the AGM and final dividend is August 20, 2024.
お知らせ • Aug 01National Peroxide Limited, Annual General Meeting, Aug 27, 2024National Peroxide Limited, Annual General Meeting, Aug 27, 2024.
お知らせ • Jul 25National Peroxide Limited to Report Q1, 2025 Results on Jul 31, 2024National Peroxide Limited announced that they will report Q1, 2025 results on Jul 31, 2024